摘要
目的 探讨p5 3 ,p2 1蛋白在乳癌中表达的临床意义。方法 用免疫组化SP法对 2 0例癌旁乳腺组织和 6 9例乳癌组织中p5 3和p2 1蛋白进行半定量检测。结果 癌旁乳腺组织中p5 3和p2 1表达阴性 ;乳腺癌组织中p5 3和p2 1阳性率分别为 47.8%和 43 .5 % ;随细胞分化程度降低 ;p5 3表达阳性率明显升高 ,p2 1表达的阳性率明显降低。p2 1表达的阳性率在有、无淋巴结转移组差异显著 (P <0 .0 5 ) ;p5 3阳性、p2 1阴性组术后 5年无瘤生存率明显低于p5 3阴性、p2 1阳性组 (P <0 .0 5 ) ;在乳癌组织中p2 1表达与p5 3明显相关(P <0 .0 5 )。结论 p5 3和p2
Objective To assess the clinical significance of the expression of p53, p21 protein in breast cancer (BC). Method The expression levels of p53, p21 proteins were examined by immunohistochemical (IHC) SP techniques in 69 BC specimen and 20 paracancinoma breast tissue. Result p53 and p21 proteins were failed to be observed in the paracancer tissue. p53 protein was found in 47.8% of BC, while p21 protein in 43.5% of BC. Along with the declined of BC cell differentiation degree, p53 expression increased significantly and p21 expression declined obviously. Expression of p21 was lower in patients with lymph node metastasis than that in patients without lymph node metastasis (P<0.05). Disease-free survival rate was lower in patients with p53-positive, p21-negative tumors than that in patients with p53-negative, p21-positive tumors (P<0.05). In BC tissue, expression of p21 correlated with expression of p53 (P<0.05). Conclusions The expression of p53 and p21 gene proteins can be used to assess differentiation degree of BC cells, and the prognosis of patients with BC.
出处
《中国普通外科杂志》
CAS
CSCD
2001年第5期415-418,共4页
China Journal of General Surgery
